Oxford Global Conferences received excellent feedback from the 2014 Drug Discovery USA Congress

Posted: 8 January 2015 | Oxford Global Conferences

Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA…

Oxford Global Conferences were proud to present the Drug Discovery USA Congress this October in Boston, USA. The congress brought together a host senior level experts to discuss recent developments in the industry and debate the best strategies and solutions to improve drug discovery going forward.

Over 150 delegates attended the two day congress held at the Hyatt Boston Harbor Hotel. The two day congress showcased 40 presentations and case studies which focused on four key interactive streams:

  • R&D Models For The Future
  • Screening & Assays: Enabling Technologies
  • Discovery Chemistry & Drug Design
  • Supporting Innovation: Translational Approaches & Informatics Tools

Presentations included:

Christopher J. Winrow, Director, Neuroscience Department, Merck & Co., Inc. Translational Approaches To Novel Insomnia Treatments

David Hayes, Director Discovery Sciences, AstraZeneca Assay Technologies: Case Studies Including Biophysical & Mass Spec Techniques

Mark Hurle, Senior Scientific Investigator, Computational Biology, GSK Computational Drug Repositioning: Hopes, Hints And Hyperbole

Lyn Jones, Head Rare Diseases Chemistry, Head Chemical Biology, Pfizer Chemical Biology And Medicinal Chemistry For Rare Disease Research

Tim Hoctor, Vice President, Life Science Professional Services, Elsevier Life Science Solutions Improving R&D Outcomes: Extracting Actionable Information

The congress offered a great platform for learning and networking. Fellow drug discoverers were able to come together to share opinions, experiences and knowledge within the industry. Attendees were able to interact with each other to establish new connections. The Director of Business Development at NovAlix said “The Congress provided my company with plenty of networking opportunities. We made lots of new and interesting contacts.”

Many delegates commented on the variety and quality of the presentations and case studies, the Senior Group Leader, Primary Pharmacology Group at UCB said “There was a variety of high quality presentations and plenty of great case studies. The Congress was an excellent platform to meet fellow drug-discoverers.”

We received excellent feedback on the overall organisation of the congress, Lead Consultant – Text & Data Analytics and Life Science Professional Services from Elsevier Life Science Solutions said “The Congress was concise and very well organised. The talks and sessions were all very relevant. There was also a great mix of presentations, meetings and free time.”

The solution providers and delegates both benefited from pre-arranged one-to-one meetings. The Senior Vice President Business Development from OnTarget Chemistry said “I enjoyed the 1-2-1 meetings. The process leading up to them was very enjoyable. I’d like to thank the Oxford Global staff for all their hard work and help.”

Following the event, we analyse statistics and feedback from attendees, and we are proud to announce that we achieved an “Above Average” or “Excellent” rating in all categories including:

  • Overall Organisation of Congress
  • Overall Services of the Oxford Global Staff
  • Relevance and Quality of Solution Providers
  • Relevance and Quality of Delegates

This is great news for everyone involved in the production of the 2014 Drug Discovery USA Congress.

After the success of the 2014 Drug Discovery USA Congress, Oxford Global Conferences are proud to announce that we will be hosting the 2nd Annual Drug Discovery USA Congress in Boston in October 2015. For further information on this or any of our upcoming congresses, please contact Danielle Dalby on +44 1865 248455 or by email on [email protected]

Related topics

Related organisations